RA Capital Management is a multi-stage investment firm primarily focused on evidence-based investing in healthcare, biotechnology, and life science companies developing drugs, medical devices, diagnostics, services, and research tools. The firm also invests in planetary health, supporting companies from discovery through commercialization in both public and private markets.
69% of their portfolio is in Biotech & Life Sciences. Deal activity increased 225% year-over-year (13 deals in the last 12 months). Average disclosed round size is $99.9M (across 57 rounds with reported amounts).
Portfolio
61
Fund Size
$12.6B
Top Stage
Series B
Last 12 Mo
13
Team
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
61 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| SSlate Medicines | Series A | $130M | Feb 2026 |
 Avalanche Energy | Series B | $29M | Feb 2026 |
| EEvodiaBio | Series A | $6M | Dec 2025 |
 Triana Biomedicines | Series B | $120M | Dec 2025 |
 Bambusa Therapeutics | Series A | — | Nov 2025 |
| RRani Therapeutics | Series C | $60.3M | Oct 2025 |
 Sparrow Pharmaceuticals | Series B | $95M | Sep 2025 |
 Gameto | Series C | $44M | Aug 2025 |
| SSAB Biotherapeutics, Inc. | Series B | $175M | Jul 2025 |
 Commons Clinic | Series B | $26M | Jun 2025 |
 Imbria Pharmaceuticals | Series B | $57.5M | Apr 2025 |
 Surrozen, Inc. | Series D | $175M | Mar 2025 |
 Curevo Vaccine | Series B | $110M | Mar 2025 |
| Bambusa Therapeutics | Series A | — | Feb 2025 |
| VVerdiva Bio | Series A | $410M | Jan 2025 |
 Bluejay Therapeutics | Series C | $182M | May 2024 |
 Diagonal Therapeutics | Series A | $128M | Apr 2024 |
 Claris Bio | Series A | $57M | Jan 2024 |
 Amplifier Therapeutics | Series A | $33.3M | Oct 2023 |
| Commons Clinic | Series A | $19.5M | Oct 2023 |
| CCompass Pathways | Series D | $285M | Aug 2023 |
 Gracell Biotechnologies Inc. | Growth | $150M | Aug 2023 |
| CCarmot Therapeutics | Series E | $150M | May 2023 |
 Cortica, Inc. | Growth | $75M | Apr 2023 |
 Hemab Therapeutics | Series B | $135M | Feb 2023 |
Page 1 of 3
Top Co-Investors
Janus Henderson Investors9 shared
Perceptive Advisors7 shared
Logos Capital7 shared
OrbiMed7 shared
Atlas Venture7 shared
Vivo Capital6 shared
Invus6 shared
Bain Capital Life Sciences5 shared
Deerfield5 shared
Samsara BioCapital4 shared
Access Biotechnology4 shared
Novo Holdings4 shared
Deep Track Capital4 shared
Surveyor Capital4 shared
Cormorant Asset Management3 shared
GV (Google Ventures)3 shared
Kaiser Permanente Ventures3 shared
Polaris Venture Partners3 shared
Sands Capital3 shared
Pfizer Ventures3 shared
Last updated: 5 March 2026